Model DetailsEye - Harderian gland tumor
Model Name |
Eye - Harderian gland tumor | Strain |
(C57BL/6 x C3H)F1 |
Tumor Inducing Agent(s) |
Chemical/Drug : 1,3-butadiene |
Tumor Synonyms |
Harderian gland tumor • harderian gland tumor |
Strain Synonyms |
B6C3F1 • (C57BL/6xC3H) • F1-hybrid B6C3F1 • B6C3F1 • hybrid B6C3F1 • B6C3F1 (C3H x C57B16) • B6C3F1 hybrid |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Eye - Harderian gland | Male |
15% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Male |
25% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Male |
53% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Male |
77% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Male |
58% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Female |
21% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Female |
17% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Female |
40% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Female |
67% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Female |
48% |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Unspecified |
observed |
>2 years |
|
Goodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7 |
| Eye - Harderian gland | Female |
20% (10 of 50 mice) |
103 weeks |
|
Fred C, Cancer Res 2008 Oct 1;68(19):8014-21 |
| Eye - Harderian gland | Female |
14% (7 of 50 mice) |
103 weeks |
|
Fred C, Cancer Res 2008 Oct 1;68(19):8014-21 |
| Eye - Harderian gland | Female |
30% (15 of 50 mice) |
103 weeks |
|
Fred C, Cancer Res 2008 Oct 1;68(19):8014-21 |
| Eye - Harderian gland | Female |
40% (20 of 50 mice) |
103 weeks |
|
Fred C, Cancer Res 2008 Oct 1;68(19):8014-21 |